Clinical Trial Update: UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies [Phase 1]

View source ↗

Summary

Ubix Therapeutics is recruiting for a Phase 1 study of UBX-303061 to treat relapsed/refractory B-cell malignancies. The document notes ongoing enrollment with n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• UBX-303061

Snippet

Sponsor: Ubix Therapeutics, Inc. | Conditions: Relapsed/Refractory B-cell Malignancies | Phase 1 | Status: RECRUITING